CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-18 | Dunn Judith Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2023-05-18 | Rosenberg Adam Joseph Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2023-05-18 | Levin Andrew David Executive Chairman | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2023-05-18 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2023-03-10 | Morisset Valerie EVP, R&D and CSO | Option exercise | +255,219 | $0.00 | $510 | 405,541 |
| 2023-03-10 | Morisset Valerie EVP, R&D and CSO | Option exercise | +61,191 | $0.00 | $12 | 466,732 |
| 2023-03-10 | Morisset Valerie EVP, R&D and CSO | Option exercise · Stock Option (Right to Buy) | −255,219 | 5,431 | ||
| 2023-03-10 | Morisset Valerie EVP, R&D and CSO | Option exercise · Stock Option (Right to Buy) | −61,191 | 61,190 | ||
| 2022-10-31 | Morisset Valerie EVP, R&D and CSO | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2022-10-31 | Azelby Robert President & CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2022-10-31 | Lavelle Erin COO & CFO | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2022-10-31 | Bucher James B EVP and General Counsel | Grant or award · Stock Option (Right to Buy) | +95,000 | 95,000 | ||
| 2022-05-19 | Tate Simon Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | Ratcliffe Liam Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | PATTERSON LEONE D Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | Rosenberg Adam Joseph Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | Levin Andrew David Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | Dunn Judith Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2022-05-19 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2022-01-27 | Lavelle Erin COO & CFO | Grant or award · Stock Option (Right to Buy) | +170,000 | 170,000 |
Page 7 of 9 · 166 trades